Research on therapeutic clinical trials including immunotherapy in Triple- negative Breast cancer: A bibliometric analysis

Background Breast cancer is a common malignancy worldwide. Triple-negative breast cancer (TNBC) is a prevalent subtype of breast cancer that has poorer histological characteristics and a greater incidence of both local and distant metastases. Methods We downloaded publications on clinical trials of TNBC treatment from 1997 to 2024 and performed a bibliometric analysis using Bibliometrix in R and VOSviewer in order to demonstrate the prospects, highlights, and trends of TNBC treatment options. Results There were 1907 publications in all, most of which were from China, Italy, and the United States. The number of annual publications has increased dramatically since 2010. The focus of TNBC clinical trial research has shifted from understanding the biology, such as breast cancer subtyping and genotyping, to novel therapeutic approaches. The major advancement in clinical trials is the switch from late-stage palliative treatment to early preoperative neoadjuvant therapy, as more TNBC cases are discovered at an early stage. Immunotherapy is also highlighted with additional alternatives for advanced or metastasized TNBC, such as targeted inhibitors with unusual mutation rates and antibody drug conjugates (ADC). Conclusions This investigation made it apparent how immunotherapy has recently made major advancements in TNBC treatment plans and how ADCs, or targeted therapies, are currently popular for TNBC. By identifying significant papers, comprehending trending topics, and collaborating across multiple disciplines, this study may accelerate research on TNBC therapy options.